Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Mink Intersects 7.1 Meters of 0.44% Ni, 0.28% Cu, 0.06% Co in Massive Sulphide at Warren Property (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Climb Bio Inc CLYM

Healthcare Biotechnology
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the... see more

Recent & Breaking News (NDAQ:CLYM)

Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates 

GlobeNewswire 6 days ago

Climb Bio to Present at Upcoming Investor Conferences

GlobeNewswire February 5, 2026

Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026

GlobeNewswire January 8, 2026

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 25, 2025

Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire November 6, 2025

Climb Bio to Present at Upcoming Investor Conferences

GlobeNewswire November 3, 2025

Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy

GlobeNewswire October 21, 2025

Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025

GlobeNewswire October 17, 2025

Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer

GlobeNewswire October 1, 2025

Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN

GlobeNewswire September 29, 2025

Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025

GlobeNewswire September 4, 2025

UPDATE - Climb Bio to Present at Upcoming September 2025 Investor Conferences

GlobeNewswire August 25, 2025

Climb Bio to Present at Upcoming September 2025 Investor Conferences

GlobeNewswire August 25, 2025

Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire August 12, 2025

Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer

GlobeNewswire June 18, 2025

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 19, 2025

Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire May 14, 2025

Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX, ACB

PR Newswire May 8, 2025

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

GlobeNewswire April 1, 2025

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference

GlobeNewswire March 27, 2025

Podcasts